EUVIMEDSkopri EUVIMED
Crossref

The MAD2B‐APC / C‐MDM2 axis mediates acute kidney injury by modulating p53

Zhe Hao iD, Qian Yuan, Hui Tang, Chuntao Lei, Yu Chen, Hua Su, Chun Zhang iD

The FEBS Journal · 2023

DOI: 10.1111/febs.16786 ↗

At a glance

Journal article in The FEBS Journal, 2023. Written by Zhe Hao and 6 co-authors. Institution: Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Major MEDLINE topics: Tumor Suppressor Protein p53, Acute Kidney Injury. Cited 4 times so far (Crossref); 47 references. Funded by: National Natural Science Foundation of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

P53 is a master regulator modulating the progression of acute kidney injury (AKI). However, the mechanism underlying p53 regulation in AKI needs further investigation. Mitotic arrest deficient 2 like 2 (MAD2B) is a subunit of DNA polymerase ζ. Its role in AKI remains unclear. Here, we demonstrated that MAD2B acted as an endogenous suppressor of p53. MAD2B conditional knockout augmented the upregulation of p53 in kidneys suffering from cisplatin‐induced AKI, therefore promoting the deterioration of renal function, G1 phase arrest and apoptosis of proximal tubular epithelial cells. Mechanistically, MAD2B deficiency activated the anaphase‐promoting complex/cyclosome (APC/C), which is an inhibitor of the well‐characterized p53‐directed E3 ligase MDM2. The decreased MDM2 diminished the degradation of p53, resulting in the upregulation of p53. The APC/C antagonist proTAME ameliorated cisplatin‐induced AKI and blocked MAD2B knockdown‐induced p53 upregulation and reduced cell cycle arrest and apoptosis in tubular epithelial cells by upregulating MDM2. These results indicate that MAD2B is a novel target for inhibiting p53 and ameliorating AKI.

Subjects

MeSH terms (MEDLINE)

Tumor Suppressor Protein p53Acute Kidney InjuryHumansAnaphase-Promoting Complex-CyclosomeMad2 ProteinsCisplatinApoptosisProto-Oncogene Proteins c-mdm2

Author keywords

AKIMAD2Bapoptosiscell cycle arrestp53

Substances

Anaphase-Promoting Complex-CyclosomeTumor Suppressor Protein p53Mad2 ProteinsCisplatinMDM2 protein, humanProto-Oncogene Proteins c-mdm2

Authors and institutions

  • Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID profiles: Zhe Hao, Chun Zhang

Funding

  • National Natural Science Foundation of China

Cite

APA

Hao, Z., Yuan, Q., Tang, H., Lei, C., Chen, Y., Su, H., & Zhang, C. (2023). The MAD2B‐APC / C‐MDM2 axis mediates acute kidney injury by modulating p53. The FEBS Journal. https://doi.org/10.1111/febs.16786

Vancouver

Hao Z, Yuan Q, Tang H, Lei C, Chen Y, Su H, et al. The MAD2B‐APC / C‐MDM2 axis mediates acute kidney injury by modulating p53. The FEBS Journal. 2023. doi:10.1111/febs.16786

BibTeX
@article{Hao2023,
  author = {Hao, Zhe and Yuan, Qian and Tang, Hui and Lei, Chuntao and Chen, Yu and Su, Hua and Zhang, Chun},
  title = {The MAD2B‐APC / C‐MDM2 axis mediates acute kidney injury by modulating p53},
  journal = {The FEBS Journal},
  year = {2023},
  doi = {10.1111/febs.16786}
}
Start for free →